Exeporfinium
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2012 (NCT01592214)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
C[N+](C)(C)CCCOc1ccc(-c2c3nc(cc4ccc([nH]4)c(-c4ccc(OCCC[N+](C)(C)C)cc4)c4nc(cc5ccc2[nH]5)C=C4)C=C3)cc1- Mol. weight
- 694.92 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3824393 ↗
Also known as
- xf-73
- xf-73
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03915470 | Phase 2 | Jun 11, 2019 | Destiny Pharma Ltd |
| NCT02282605 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2014 | Destiny Pharma Ltd |
| NCT01592214 | Phase 1 | Aug 1, 2012 | National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Destiny Pharma Ltd | For profit | 2 | 2 | 1 | 2014 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2012 |
2 organizations
Page 1 / 1